Results for tag: "Homocystinuria Drug"

Homocystinuria is a rare genetic disorder that affects the metabolism of the amino acid homocysteine. It is caused by a deficiency of the enzyme cystathionine beta-synthase, which is responsible for the conversion of homocysteine to cystathionine. Treatment of homocystinuria involves the use of drugs to reduce the levels of homocysteine in the blood. These drugs include betaine, vitamins B6 and B12, and folic acid. In addition, drugs such as pyridoxine, cysteine, and taurine may be used to reduce the levels of homocysteine in the body. The homocystinuria drug market is a niche market within the larger liver and kidney disorders drugs market. It is focused on providing treatments for homocystinuria, a rare genetic disorder. The market is composed of a variety of drugs, including betaine, vitamins B6 and B12, and folic acid, as well as other drugs such as pyridoxine, cysteine, and taurine. Some companies in the homocystinuria drug market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more